The number of people making five or more emergency visits to hospital a year with lung difficulties has almost tripled in some parts of England, an analysis has found. The charity Asthma + Lung UK ...

China: Severe asthma remains a major healthcare challenge, contributing to increased morbidity, reduced quality of life, and ...

This study evaluates whether early CR at 1 year after inhaled corticosteroid (ICS) initiation influences lung function decline and exacerbation risk in asthma. Methods This retrospective cohort study ...

It also lowers the risk of an asthma attack. Airsupra comes as an aerosol that you inhale through your mouth via the Airsupra inhaler. Airsupra contains the active ingredients albuterol and ...

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

Inhaled corticosteroids (ICS) are the most effective anti-inflammatory drug. In childhood and adult asthma, early intervention with ICS could facilitate better control of asthma symptoms.

Subgroup analysis suggests that ECFC from patients with COPD on inhaled corticosteroids (ICS) (n=14; eight on ICS) exhibited significantly reduced senescence (Senescence-associated-beta galactosidase ...

There are also age-related issues leading to decreased disease control such as non-adherence, tobacco use, difficulty in using inhalers and corticosteroid-related side effects which hinder asthma ...

Depemokimab’s PDUFA date is set for December 16, 2025, with FDA reviewing two indications. Phase 3 trials showed significant improvements in nasal polyp size and obstruction. Join Nic Chahine ...

Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?